For the millions of older adults living with dementia, the drugs most commonly prescribed to control agitation, aggression, and psychosis carry risks that may quietly outweigh their modest benefits — and the medical field is finally reckoning with how to walk that back safely. This commentary from The Lancet Healthy Longevity places the deprescribing question at the center of geriatric care, where it arguably belongs.
Behavioral and psychological symptoms of dementia (BPSD) affect the vast majority of patients at some point across the disease trajectory, generating enormous caregiver burden and driving costly healthcare utilization. Antipsychotics have long been the default pharmacological response despite a well-documented adverse effect profile that includes increased stroke risk, accelerated cognitive decline, sedation, falls, and elevated all-cause mortality — risks significant enough that regulatory agencies in multiple countries issued black-box warnings for this population over a decade ago. The commentary frames deprescribing not merely as risk mitigation but as an active, structured clinical strategy requiring defined protocols, caregiver education, and non-pharmacological substitution.
This piece arrives at a meaningful inflection point. A growing body of evidence — including gradual tapering trials and systematic reviews — suggests that a substantial proportion of dementia patients can have antipsychotics successfully discontinued without meaningful worsening of behavioral symptoms, particularly when robust psychosocial interventions are in place. Yet real-world prescribing rates remain stubbornly high, pointing to a persistent implementation gap rooted in clinician inertia, caregiver anxiety, and institutional time constraints. The commentary's chief value is in spotlighting that gap rather than presenting new trial data, which means its conclusions are inherently opinion-forward and limited in evidentiary weight. Still, its publication in a high-impact longevity-focused journal signals growing editorial consensus that deprescribing deserves the same clinical rigor currently reserved for initiating treatment — an incremental but potentially practice-shifting reframe for geriatric medicine.
